Core Insights - Annovis Bio Inc. has appointed Hui Liu as Director of Biostatistics to enhance the integrity of its clinical trials as it advances its pivotal Phase 3 trial for Alzheimer's disease [2][3] Company Overview - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease [1][3] - The company is headquartered in Malvern, Pennsylvania, and is dedicated to improving patient outcomes and quality of life through innovative therapies [3] Appointment of Hui Liu - Hui Liu brings over 19 years of experience in clinical trial design, analysis, and reporting across various therapeutic areas, with expertise in statistical methodology [2] - Liu's role will involve authoring statistical analysis plans, developing programming specifications, and interpreting complex data to support regulatory submissions [2] - The appointment is seen as a reinforcement of the company's commitment to scientific excellence and robust regulatory submissions [2]
Annovis Bio Appoints Hui Liu as Director of Biostatistics